Recently, researchers and scientists established a robust genomic classification for skull base chordoma. This rare sarcoma originates from the notochord and typically exhibits slow growth. Specifically, the study used copy-number events to define four distinct molecular clusters. These groups include C1, C9, C7, and C2. Because the scientists analyzed two independent cohorts, the results are also stable and reproducible. Consequently, this skull base chordoma subtyping provides a unifying biological framework for clinicians and pathologists.

Molecular Clusters and Skull Base Chordoma Subtyping

Each cluster also exhibits unique genomic architectures and transcriptomic profiles. For instance, cluster C9 shows significant chromosomal losses, and this particularly involves the CDKN2A region. In contrast, cluster C7 features chromosome 7 gains, but cluster C2 demonstrates gains in both chromosomes 2 and 7. Furthermore, the C2 cluster displays up-regulation of Sonic Hedgehog signaling, and both C2 and C9 are also enriched in cell-cycle-related genes. Therefore, these findings highlight potential therapeutic vulnerabilities and drug targets for patients.

In addition, the clusters explain nearly one-third of transcriptional variance, and they also correlate with markers like chromosomal instability and immune scores. Indeed, this classification might guide future personalized strategies, so doctors can tailor therapies for chordoma patients. Finally, while chordomas have unique genomic patterns, they also share certain aberrations with other sarcomas. Although these tumors are rare, this research also offers hope for improved management and survival.

Frequently Asked Questions

What are the four genomic clusters of skull base chordoma?

The clusters are C1 (CN-stable), C9 (losses of chr9/CDKN2A), C7 (chr7 gain), and C2 (gains of chromosomes 2 and 7).

How does this genomic subtyping impact chordoma treatment?

The classification identifies specific pathways, such as Sonic Hedgehog signaling and cell-cycle genes, which could serve as targets for novel targeted therapies.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Baluszek S et al. The copy-number events in skull base chordoma stratify tumours into four biologically coherent groups. Neoplasia. 2026 Jun 12. doi: undefined. PMID: 42284679.

2. Bai J et al. Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival. Nat Commun. 2021;12(1):757.

3. Luo L et al. Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target. Oncogene. 2020;39(31):5324-5337.